NVO vs. TMUS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at NVO and TMUS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
NVO trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, TMUS is a standard domestic listing.
| Symbol | NVO | TMUS |
|---|---|---|
| Company Name | Novo Nordisk A/S | T-Mobile US, Inc. |
| Country | Denmark | United States |
| GICS Sector | Health Care | Communication Services |
| GICS Industry | Pharmaceuticals | Wireless Telecommunication Services |
| Market Capitalization | 244.20 billion USD | 283.31 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | April 30, 1981 | April 19, 2007 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of NVO and TMUS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | NVO | TMUS |
|---|---|---|
| 5-Day Price Return | 4.72% | -2.51% |
| 13-Week Price Return | -17.05% | 4.53% |
| 26-Week Price Return | -37.87% | -4.41% |
| 52-Week Price Return | -60.23% | 28.15% |
| Month-to-Date Return | 15.71% | 5.59% |
| Year-to-Date Return | -41.70% | 14.05% |
| 10-Day Avg. Volume | 6.68M | 3.71M |
| 3-Month Avg. Volume | 6.63M | 4.42M |
| 3-Month Volatility | 65.20% | 23.82% |
| Beta | 1.52 | 0.61 |
Profitability
Return on Equity (TTM)
NVO
77.86%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
NVO’s Return on Equity of 77.86% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
TMUS
19.69%
Wireless Telecommunication Services Industry
- Max
- 27.67%
- Q3
- 18.94%
- Median
- 13.35%
- Q1
- 6.38%
- Min
- -8.07%
In the upper quartile for the Wireless Telecommunication Services industry, TMUS’s Return on Equity of 19.69% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
NVO
35.61%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
NVO’s Net Profit Margin of 35.61% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
TMUS
14.53%
Wireless Telecommunication Services Industry
- Max
- 17.18%
- Q3
- 13.67%
- Median
- 9.33%
- Q1
- 4.43%
- Min
- -5.10%
A Net Profit Margin of 14.53% places TMUS in the upper quartile for the Wireless Telecommunication Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
NVO
45.78%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
NVO’s Operating Profit Margin of 45.78% is exceptionally high, placing it well above the typical range for the Pharmaceuticals industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.
TMUS
23.08%
Wireless Telecommunication Services Industry
- Max
- 29.85%
- Q3
- 23.51%
- Median
- 20.46%
- Q1
- 16.06%
- Min
- 9.07%
TMUS’s Operating Profit Margin of 23.08% is around the midpoint for the Wireless Telecommunication Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | NVO | TMUS |
|---|---|---|
| Return on Equity (TTM) | 77.86% | 19.69% |
| Return on Assets (TTM) | 24.22% | 5.78% |
| Net Profit Margin (TTM) | 35.61% | 14.53% |
| Operating Profit Margin (TTM) | 45.78% | 23.08% |
| Gross Profit Margin (TTM) | 83.95% | 63.61% |
Financial Strength
Current Ratio (MRQ)
NVO
0.78
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
NVO’s Current Ratio of 0.78 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
TMUS
1.21
Wireless Telecommunication Services Industry
- Max
- 1.26
- Q3
- 1.00
- Median
- 0.71
- Q1
- 0.60
- Min
- 0.36
TMUS’s Current Ratio of 1.21 is in the upper quartile for the Wireless Telecommunication Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio (MRQ)
NVO
0.59
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
NVO’s Debt-to-Equity Ratio of 0.59 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
TMUS
1.45
Wireless Telecommunication Services Industry
- Max
- 2.92
- Q3
- 2.15
- Median
- 1.57
- Q1
- 0.91
- Min
- 0.44
TMUS’s Debt-to-Equity Ratio of 1.45 is typical for the Wireless Telecommunication Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
NVO
149.07
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
With an Interest Coverage Ratio of 149.07, NVO demonstrates a superior capacity to service its debt, placing it well above the typical range for the Pharmaceuticals industry. This stems from either robust earnings or a conservative debt load.
TMUS
5.31
Wireless Telecommunication Services Industry
- Max
- 12.67
- Q3
- 6.16
- Median
- 3.95
- Q1
- 1.81
- Min
- -1.20
TMUS’s Interest Coverage Ratio of 5.31 is positioned comfortably within the norm for the Wireless Telecommunication Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | NVO | TMUS |
|---|---|---|
| Current Ratio (MRQ) | 0.78 | 1.21 |
| Quick Ratio (MRQ) | 0.56 | 1.08 |
| Debt-to-Equity Ratio (MRQ) | 0.59 | 1.45 |
| Interest Coverage Ratio (TTM) | 149.07 | 5.31 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
NVO
3.30%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
NVO’s Dividend Yield of 3.30% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
TMUS
1.29%
Wireless Telecommunication Services Industry
- Max
- 7.63%
- Q3
- 5.13%
- Median
- 3.22%
- Q1
- 2.33%
- Min
- 0.00%
TMUS’s Dividend Yield of 1.29% is in the lower quartile for the Wireless Telecommunication Services industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.
Dividend Payout Ratio (TTM)
NVO
61.60%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
NVO’s Dividend Payout Ratio of 61.60% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
TMUS
30.87%
Wireless Telecommunication Services Industry
- Max
- 145.86%
- Q3
- 109.87%
- Median
- 78.85%
- Q1
- 48.65%
- Min
- 0.00%
TMUS’s Dividend Payout Ratio of 30.87% is in the lower quartile for the Wireless Telecommunication Services industry. This suggests a conservative dividend policy, with a strategic focus on reinvesting profits for future growth.
Dividend at a Glance
| Symbol | NVO | TMUS |
|---|---|---|
| Dividend Yield (TTM) | 3.30% | 1.29% |
| Dividend Payout Ratio (TTM) | 61.60% | 30.87% |
Valuation
Price-to-Earnings Ratio (TTM)
NVO
13.91
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, NVO’s P/E Ratio of 13.91 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
TMUS
23.93
Wireless Telecommunication Services Industry
- Max
- 34.45
- Q3
- 23.52
- Median
- 16.68
- Q1
- 13.97
- Min
- 7.48
A P/E Ratio of 23.93 places TMUS in the upper quartile for the Wireless Telecommunication Services industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
Price-to-Sales Ratio (TTM)
NVO
4.95
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
NVO’s P/S Ratio of 4.95 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
TMUS
3.48
Wireless Telecommunication Services Industry
- Max
- 2.56
- Q3
- 1.94
- Median
- 1.37
- Q1
- 1.22
- Min
- 0.62
With a P/S Ratio of 3.48, TMUS trades at a valuation that eclipses even the highest in the Wireless Telecommunication Services industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
NVO
8.87
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
NVO’s P/B Ratio of 8.87 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
TMUS
4.43
Wireless Telecommunication Services Industry
- Max
- 4.87
- Q3
- 2.93
- Median
- 2.02
- Q1
- 1.33
- Min
- 0.40
TMUS’s P/B Ratio of 4.43 is in the upper tier for the Wireless Telecommunication Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | NVO | TMUS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 13.91 | 23.93 |
| Price-to-Sales Ratio (TTM) | 4.95 | 3.48 |
| Price-to-Book Ratio (MRQ) | 8.87 | 4.43 |
| Price-to-Free Cash Flow Ratio (TTM) | 23.46 | 23.69 |